Finally, using a pharmacologic approach, we identified the hypoxia-regulated lactate exporter monocarboxylate transporter 4 (MCT4) as a potential target to suppress maladaptive proinflammatory responses and halt AKI to CKD transition. Here, SLC16A3 is linked to chronic kidney disease.